Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Gynecologic Cancers
A randomized phase 3 study of first-line trastuzumab deruxtecan with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient, primary advanced or recurrent endometrial cancer: DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
Brian Slomovitz
Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
A randomized Phase 3 study of first-line trastuzumab deruxtecan with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient, primary advanced or recurrent endometrial cancer: DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
Trine Jakobi Nøttrup
Poster
T-DXd
ESMO Gyn 2025 | June 19-21, 2025
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO-01)
Antonio González-Martín
Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO-01, ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)
Antonio J. González-Martín
Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan versus standard of care chemotherapy with or without radiotherapy as adjuvant treatment for patients with HER2-expressing (IHC 3+/2+) endometrial cancer: DESTINY-Endometrial02 (DE-02; GOG-3122/ENGOT-en30)
Cara Mathews
Oral
R-DXd
ESMO Asia 2025 | December 5-7, 2025
Gynecologic Cancers
Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: A subgroup analysis of Asian patients from the phase 2, dose-optimization part of REJOICE-Ovarian01
Jung-Yun Lee
Oral
R-DXd
ESMO 2025 | October 17-21, 2025
Gynecologic Cancers
Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: Primary analysis of the phase 2, dose-optimization part of the REJOICE-Ovarian01 study
Isabelle Ray-Coquard
Mini-Oral
R-DXd
ESMO Gyn 2025 | June 19-21, 2025
Gynecologic Cancers
Raludotatug deruxtecan (R-DXd) monotherapy in
patients with heavily pretreated platinum-sensitive
ovarian cancer: Subgroup analysis of a Phase 1 study
Kathleen Moore
Poster
R-DXd
ESMO Gyn 2025 | June 19-21, 2025
Gynecologic Cancers
REJOICE-Ovarian02: A phase 1b/2 study of raludotatug deruxtecan (R-DXd) with other anticancer agents in participants with relapsed ovarian cancer after platinum-based chemotherapy
Ana Oaknin
Poster
R-DXd
ASCO GU 2026 | February 26 - 28, 2026
Gynecologic Cancers
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors
Laurence Albiges
